coz every indication adds value to the company... we already have done majority of the R&D and data looks good....diversify risk... more sales, most likely first treatment for Orphan indication.....to name few reasons....I think US alone is over a $1b opportunity...
now sure if I understood your question correctly
Ann: Dimerix Plans for Next Study in Diabetic Kidney Disease, page-59
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
46.0¢ |
Change
-0.005(1.08%) |
Mkt cap ! $253.1M | |||
| Open | High | Low | Value | Volume |
| 47.0¢ | 49.0¢ | 45.5¢ | $1.771M | 3.761M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 34765 | 46.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 46.5¢ | 26998 | 1 |
View Market Depth
| Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
| DXB (ASX) Chart |